The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Subgroup analysis update for the ARROW study: once-weekly carfilzomib for R/R myeloma
Here, Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, gives us an update on the subgroup analysis data for the ARROW study (NCT02412878), which compared a once-weekly vs. twice-weekly regimen of carfilzomib in combination with dexamethasone for relapsed/refractory multiple myeloma. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
